Daily Cosmetic Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Today’s top cosmetic-related research spans a randomized clinical trial optimizing ablation for benign thyroid nodules, a mechanistically rigorous platform enabling transdermal collagen delivery for skin rejuvenation, and a prospective cohort revealing barrier, antimicrobial peptide, and microbiome disruptions under EGFR inhibitor therapy. Together, they advance procedural outcomes, topical anti-aging delivery science, and supportive dermatologic care.
Research Themes
- Energy-based and sclerosing ablation synergy for benign thyroid nodules
- Transdermal delivery innovation for anti-aging collagen therapy
- EGFR inhibitor–associated skin barrier, AMP, and microbiome dysregulation
Selected Articles
1. Randomized Clinical Trial of Ultrasound-Guided Microwave Ablation Combined With Lauromacrogol Ablation of Thyroid Cystic-Solid Nodules.
In a single-center randomized trial (n=88), ultrasound-guided microwave ablation combined with lauromacrogol ablation achieved higher 6- and 12-month volume reduction rates, shorter ablation time, and lower energy per unit volume than microwave ablation alone. Symptom and cosmetic scores and overall complications (13.64% vs 34.21%) favored combination therapy, with no significant changes in thyroid function.
Impact: This randomized evidence supports a combined energy-based and sclerosing strategy for cystic-solid thyroid nodules, improving efficacy, safety, and cosmetic outcomes over microwave ablation alone.
Clinical Implications: For predominantly cystic thyroid nodules, clinicians can consider combining microwave ablation with lauromacrogol ablation to achieve greater volume reduction, fewer complications, and better symptom and cosmetic outcomes without impairing thyroid function.
Key Findings
- Combination MWA+LIA achieved significantly higher volume reduction at 6 and 12 months versus MWA alone.
- Ablation time and energy per unit volume were lower with combination therapy.
- Symptom and cosmetic scores improved more, and overall complications were lower (13.64% vs 34.21%).
- No significant postoperative changes in TSH, FT3, or FT4 in either group.
- Subgroup analysis: greater benefit in predominantly cystic nodules.
Methodological Strengths
- Randomized allocation with 12-month follow-up and multiple objective endpoints.
- Predefined comparison of procedural metrics, efficacy, safety, and thyroid function.
Limitations
- Single-center trial with a modest sample size (n=88).
- Blinding and allocation concealment details not reported.
- Long-term durability beyond 12 months not established.
Future Directions: Multicenter, adequately powered RCTs with longer follow-up, cost-effectiveness analyses, and imaging-guided selection criteria are warranted.
INTRODUCTION: Thyroid cystic-solid nodules are common thyroid disorders. Ultrasound-guided microwave ablation (MWA) is widely used to treat benign nodules; however, its efficacy remains limited for larger nodules when used alone. While lauromacrogol ablation (LIA) can effectively address cystic nodules, the clinical value of combining MWA with LIA remains unclear. This randomized clinical trial aims to evaluate the treatment efficacy of ultrasound-guided MWA combined with LIA in treating thyroid cystic-solid nodules and to evaluate its association with thyroid function indices. METHODS: A single-center randomized clinical trial was conducted, and a total of 88 patients with thyroid cystic-solid nodules were selected from January 2022 to January 2024 and randomly divided into two groups: the MWA group (44 cases, treated with MWA alone) and the MWA + LIA group (44 cases, treated with MWA combined with LIA). Procedure-related parameters, volume reduction rate, thyroid function indicators including thyroid stimulating hormone, free triiodothyronine, and free thyroxine, symptom scores, cosmetic scores, and complication rates were compared between groups. Patients were followed for 12 mo to assess efficacy and safety. Pearson correlation analysis was used to evaluate the relationship between procedure-related parameters and treatment outcomes. RESULTS: Volume reduction rate in the MWA + LIA group at 6 and 12 mo postoperatively was significantly higher than that in the MWA group (both P < 0.05), and the ablation time and energy consumption per unit volume were lower than those in the MWA group (P < 0.05). Subgroup analysis showed that the combined treatment was more effective for predominantly cystic nodules (P < 0.05). There were no apparent changes in thyroid function indicators in either group postoperatively (P > 0.05). The symptom scores, cosmetic scores, and overall complication rate (13.64% vs. 34.21%) in the MWA + LIA group were lower than those in the MWA group (P < 0.05). Correlation analysis indicated that ablation time and energy per unit volume were negatively correlated with treatment efficacy (P < 0.05). CONCLUSIONS: Ultrasound-guided MWA combined with LIA is associated with higher treatment efficacy for thyroid cystic-solid nodules, particularly effective for predominantly cystic nodules. This approach is associated with fewer complications, higher safety profiles, and no obvious alterations in thyroid function indices, compared to MWA alone. Future studies should include larger sample sizes and longer follow-up to validate long-term outcomes.
2. Breaching the Skin Barrier: Efficient Transdermal Delivery of Natural Collagen for Aging Skin Rejuvenation.
A ginsenoside Rh2-based liposomal system enhanced dermal delivery of natural collagen by more than fourfold while preserving its triple-helix structure, and reversed photoaging features in mice by reducing wrinkles and improving elasticity. Histology corroborated UV damage mitigation and collagen regeneration, highlighting a noninvasive anti-aging platform.
Impact: This work addresses a long-standing barrier in cosmetic dermatology—transdermal collagen delivery—through a mechanistically validated, structure-preserving liposome that demonstrates functional rejuvenation in vivo.
Clinical Implications: Provides a translational rationale for developing topical collagen products with clinically meaningful dermal bioavailability; human safety, stability, and efficacy studies are the next step.
Key Findings
- Rh2-based liposomes increased collagen transdermal delivery >4-fold versus free collagen.
- Circular dichroism showed intact collagen triple-helix after encapsulation.
- In photoaged mice, topical Rh2-CLs reduced wrinkle formation and improved elasticity.
- Histology indicated mitigation of UV-induced damage and promotion of collagen regeneration.
Methodological Strengths
- Multi-level validation including physicochemical characterization and in vivo functional outcomes.
- Structural integrity assessment (circular dichroism) linking formulation to preserved bioactivity.
Limitations
- Preclinical mouse model without human clinical data.
- Duration of topical regimen and long-term safety not detailed in the abstract.
- Scalability, stability, and regulatory considerations remain to be addressed.
Future Directions: Conduct ex vivo human skin permeation, dose-ranging safety studies, and randomized clinical trials in photoaging; evaluate long-term safety and product stability.
The supplementation of exogenous collagen is an effective strategy for combating skin aging─a complex physiological process characterized by the continuous degradation of endogenous collagen─its therapeutic efficacy has been severely limited due to poor transdermal permeability. In this study, we developed a novel noninvasive transdermal delivery system (Rh2-CLs) that effectively and safely delivers natural collagen via a novel liposome formulation for aging skin rejuvenation. The permeability of collagen was significantly enhanced by the encapsulation in the optimized liposomes, demonstrating a more than 4-fold improvement in transdermal delivery efficiency compared to free collagen. Circular dichroism spectroscopy confirmed that the encapsulation of liposomes did not disrupt the integrity of the collagen triple-helical structure, thus maintaining its original bioactivity. In a photoaged mouse model, the topical application of Rh2-CLs markedly reduced skin wrinkling and improved skin elasticity. Histological assessments revealed that Rh2-CLs effectively alleviated UV-induced damage and promoted the rapid restoration of skin structure and function through the supplementation and induction of collagen regeneration. In summary, the ginsenoside Rh2-based liposome platform offers a safe, efficient, and noninvasive strategy for transdermal collagen delivery, demonstrating considerable potential for applications in skin regeneration and cosmetic dermatology.
3. Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors.
In 84 EGFRI-treated patients followed up to 48 weeks, skin barrier metrics worsened (TEWL and pH increased; pigmentation decreased), cAEs were common (94.05%), RNase-7 levels declined at 6 months, and Corynebacterium kroppenstedtii increased. Elasticity and sebum showed no significant changes.
Impact: By integrating barrier biophysics, AMP profiling, and microbiome dynamics, this study elucidates mechanisms underlying EGFRI-related cAEs and highlights targets for supportive interventions.
Clinical Implications: Findings support early barrier-repair strategies (e.g., emollients, pH optimization), monitoring for dysbiosis, and stewardship around antimicrobial use in EGFRI-treated patients.
Key Findings
- cAEs were frequent with a cumulative incidence of 94.05%.
- TEWL and skin pH increased, and pigmentation decreased during treatment.
- RNase-7 levels significantly decreased at 6 months; hBD-3 changes were not significant.
- Corynebacterium kroppenstedtii increased at months 1 and 6; other key taxa showed no significant shifts.
Methodological Strengths
- Prospective longitudinal design with objective skin biophysical measurements up to 48 weeks.
- Multi-modal assessment including AMP quantification via tape-stripping and 16S rRNA microbiome profiling.
Limitations
- AMP (n=15) and microbiome (n=18) sub-studies had small samples, limiting power.
- Heterogeneity of cancer types and EGFRIs; lack of a matched non-EGFRI control group.
- Observational design precludes causal inference.
Future Directions: Larger, controlled cohorts and interventional trials testing barrier-repair and microbiome-modulating strategies; strain-level or metagenomic profiling to refine targets.
INTRODUCTION: Epidermal growth factor receptor inhibitors (EGFRIs) are targeted therapies for solid cancers. Their use is associated with cutaneous adverse events (cAEs). This study aimed to investigate cAEs and changes in skin biophysics reflecting the skin barrier function, alterations in antimicrobial peptides (AMPs), and the skin microbiome in patients undergoing treatment with EGFRIs. METHODS: A 2-year prospective cohort study was conducted involving patients receiving EGFRIs for solid cancers. cAEs and skin biophysical properties, including transepidermal water loss (TEWL), skin pH, elasticity, sebum, and pigmentation, were measured at baseline and follow-up visits up to 48 weeks. AMPs were assessed using a tape-stripping technique from the cheeks at months 0, 1, and 6, with protein assays and ELISA to determine the levels of human beta-defensin (hBD)-3 and ribonuclease (RNase)-7. Skin microbiome analysis was performed through 16S rRNA sequencing of cheek swabs collected at months 0, 1, and 6. RESULTS: Eighty-four patients were enrolled. The cumulative incidence of cAEs was 94.05%. Skin biophysical properties showed significantly increased TEWL and pH, decreased pigmentation, and no significant changes in elasticity and sebum. AMP analysis from 15 patients revealed significant reduction of RNase-7 levels after 6 months into EGFRIs, while hBD-3 level change was insignificant. A microbiome study from 18 patients showed statistically increased Corynebacterium kroppenstedtii at months 1 and 6, while Cutibacterium acnes, Corynebacterium aurimucosum, Staphylococcus epidermidis, and Staphylococcus aureus were not significantly different among groups. CONCLUSION: Treatment with EGFRIs compromises skin barrier function and AMP production, leading to skin microbiota changes.